Regarding BC molecular subtype, 34 (31.77%) patients had luminal A, 36 (33.64%) had luminal B HER2-negative, 6 (5.61%) had luminal B HER-2-positive, 21 (19.63%) had HER2-enriched, and 10 (9.35%) had triple-negative BC. The gene discussed is ERBB2; the disease is breast cancer.